Every 10-Q that aTyr Pharma, Inc. (ATYR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ATYR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATYR filings page.
aTyr Pharma is a clinical-stage biotech focused on tRNA synthetase biology for fibrosis and inflammation. For the quarter ended June 30, 2026, it reported a consolidated net loss of $10.3 million (basic and diluted net loss per share of $0.11) and total operating expenses of $10.9 million, with research and development at $6.7 million and general and administrative at $4.1 million.
Cash, cash equivalents, restricted cash and available-for-sale investments totaled $58.9 million, and the company believes this will fund material cash requirements for at least one year. Net cash used in operating activities was $21.9 million for the first half of 2026. aTyr maintains an at-the-market equity program but did not use it in the period.
Lead candidate efzofitimod missed the primary endpoint in the prior EFZO-FIT Phase 3 pulmonary sarcoidosis trial but showed nominal improvements in several clinical measures. After FDA feedback, aTyr plans a new global Phase 3 study using forced vital capacity as the primary endpoint. The company is also running a Phase 2 SSc-ILD study (EFZO-CONNECT) and advancing ATYR0101 into IND-enabling work. A restructuring approved in August 2026 will reduce headcount by about 60% to 20 employees, with estimated $4.2 million in severance-related charges and expected annualized operating expense reductions of about $13 million. Rights to develop and commercialize efzofitimod in Japan reverted to aTyr following termination of its Kyorin collaboration, and the company disclosed ongoing putative securities class actions related to efzofitimod.
aTyr Pharma (ATYR) reported Q3 2025 results showing continued investment in its pipeline and a larger loss as it advances efzofitimod. License and collaboration revenue was $190 thousand. Research and development expense rose to $22.1 million, and general and administrative expense was $4.8 million, leading to a net loss of $25.7 million (basic and diluted net loss per share $0.26).
Cash, cash equivalents and available-for-sale investments totaled $92.9 million as of September 30, 2025. Year-to-date, the company raised $66.4 million via its Jefferies at‑the‑market program, selling 13,887,177 shares at a weighted‑average price of $4.94. Operating cash use for the first nine months was $49.8 million. Shares outstanding were 97,986,634 as of September 30, 2025.
The company announced that the Phase 3 EFZO-FIT study in pulmonary sarcoidosis did not meet its primary endpoint, though nominal improvements were observed on certain symptom measures, and efzofitimod was generally well‑tolerated. Management plans to meet the FDA in the first quarter of 2026 to discuss a path forward. Two putative securities class action complaints were filed in October 2025; no liability has been recorded.